Danish antibody specialist Genmab has reaffirmed the more active partnering strategy instituted last year by new chief executive officer Dr Jan van de Winkel, expanding its research collaboration with Seattle Genetics for antibody-drug conjugates (ADCs) to add a new anticancer candidate to its preclinical pipeline.
The second ADC agreement with Seattle Genetics, which is attracting increasing attention with its technology for delivering anticancer agents selectively to tumour cells, mirrors the terms of the deal announced...